ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION

Title:

ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION

Document Type and Number:

WIPO Patent Application WO/2020/067399

Kind Code:

A1

Abstract:

An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

More Like This:

JP2022538117	Anti-CD33 Antibodies to Treat Cancer
JP5591279	Child chronicity arthritis associated-diseases medical treatment agent
JP2022509930	Anti-CD73 antibody, its antigen-binding fragment and their use

Inventors:

IGAWA TOMOYUKI (SG)
FENG SHU (SG)
HO SHU WEN SAMANTHA (SG)
SHIRAIWA HIROTAKE (JP)

Application Number:

PCT/JP2019/038087

Publication Date:

April 02, 2020

Filing Date:

September 27, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CHUGAI PHARMACEUTICAL CO LTD (JP)

International Classes:

C07K16/46; C12N15/09; C12P21/08; C07K16/28

Domestic Patent References:

WO2012064792A2	2012-05-18
WO2010080538A1	2010-07-15
WO2010035012A1	2010-04-01

Foreign References:

US20170274072A1	2017-09-28
EP3070168A1	2016-09-21

Other References: